Curriculum Vitae

Name:David Leslie Fogelson
Address:2730 Wilshire Blvd., Suite 325
Santa Monica, California 90403
Telephone:  (310) 828-5015
Fax:  (310) 829-3877
E-mail:  dfogelso@ucla.edu
Internet:  www.davidfogelson.com
Title:Clinical Professor, University of California at Los Angeles
Department of Psychiatry and Biobehavioral Sciences
Place of Birth:Los Angeles, California

Education

1972 B.A.University of California at Santa Cruz, honors in Biology
1977 M.D.Harvard Medical School

Postdoctoral Training:

Internship and Residencies:

1977-1978Intern in Medicine, The Faulkner Hospital, Boston, MA
1978-1979Resident in Psychiatry, Tufts University, Court Street Veterans
Administration Outpatient Clinic, Boston, MA
1979-1981Resident in Psychiatry, The Neuropsychiatric Institute,
University of California at Los Angeles
1981-1982Fellow in Psychopharmacology, McLean Hospital, Belmont,
Massachusetts, a division of Harvard Medical School

Licenses and Certification:

1977Massachusetts License Registration No. 43088
1977Diplomate of the National Board of Medical Examiners, No. 179116
1979California License registration No. G039149
1984Diplomate American Board of Psychiatry and Neurology No. 25840
2008Suboxone Certification
2016State of Georgia Physician License 72773
2018State of Utah Medical License #11051804-1205 (11/08/2018)

Hospital Appointments:

1979-1979Medical Staff Member, Braintree Hospital, Braintree, MA
1978-1979Psychiatric Staff Member, Boston State Hospital, Boston, MA
1979-1981Psychiatric Staff Member, Olive View Hospital, Los Angeles, CA
1981-1982Psychiatric Staff Member, McLean Hospital, Belmont, MA
1982-1984Medical Staff Member, Encino Hospital, Encino, CA
1982-1985Psychiatric Staff Member, Van Nuys Hospital, Van Nuys, CA
1982-1985Psychiatric Staff Member, Woodview Calabasas Hospital, Calabasas, CA
1986-1993Psychiatric Staff Member, Westwood Hospital, Westwood, CA
1987-1993Psychiatric Staff Member, St. John’s Hospital, Santa Monica, CA
1981-2009Psychiatric Staff Member, UCLA Neuropsychiatric Hospital, Westwood, CA

Awards and Honors:

1972Graduated with Honors in Biology from the University of California at Santa Cruz
1987-1991Member, Board of Directors, Obsessive Compulsive Foundation
1992Distinguished Fellow American Psychiatric Association
1996-presentElected by his peers for inclusion in Best Doctors in America®
1995Outstanding Junior Clinical Faculty Teaching Award UCLA Neuropsychiatric
Institute and Hospital Residency Program
1996Member, Scientific Advisory Board, Obsessive Compulsive Foundation of California

Major Committee Assignments:

1980-1981Secretary, Committee on Competency in Psychiatric Residency
Training, Neuropsychiatric Institute, University of California at Los Angeles
1982-1984Member, Adult Psychiatric Committee, Woodview Calabasas Hospital, Calabasas, CA
1982-1983Chairman, Adult Patient Care Evaluation Committee, Neuropsychiatric
Institute, UCLA, Los Angeles, CA
1982-1987Member, Specialty Clinics Committee, Neuropsychiatric Institute,                                     UCLA, Los Angeles, CA
1982-1987Chairman, Clinical Care Utilization Committee, Neuropsychiatric Institute, UCLA, Los Angeles, CA
1983-1985Member, Medical Records Committee, Neuropsychiatric Institute,                                     UCLA, Los Angeles, CA
1984-1986Chairman, Pharmacy Committee, Woodview Calabasas Hospital, Calabasas, CA
1990-1991Chairman, Hospital Psychiatry Committee, Southern California Psychiatric Society
1991-1998
2011-
Member, Scientific Program Committee, Southern California Psychiatric Society
1994-1996Chairman, Health Care Reform Committee, Southern California Psychiatric Society
1995-1999Member, APA Practice Research Network Scientific Advisory Committee
2016-Member, APA American Psychiatric Leadership Fellowship Committee

Memberships in Professional Societies:

1978-1993American Association for the Advancement of Science
1979American Psychiatric Association
1981American Medical Association
1992-1995West Coast College of Biological Psychiatry
1992-1995 The American Academy of Clinical Psychiatrists
2007-2012Schizophrenia International Research Society

Elected Offices:

2009-2012Southern California Psychiatric Society, Representative
2013-2014Southern California Psychiatric Society, President Elect
2014-2015Southern California Psychiatric Society, President
2016-2019Southern California Assembly Representative to the American Psychiatric Association

Major Research Interests:

  1. The clinical genetics and pathophysiology of Schizophrenia and Schizophrenia Spectrum Disorders; past medical director of a study of two hundred schizophrenic patients and their first degree relatives as part of a large collaborative research effort.
  2. Psychopharmacologic treatment of mood, anxiety and schizophrenic disorders.

Teaching Experience:

1977-1978Supervised clinical work in medicine of Tufts University medical students
at Faulkner Hospital
1979-1981Organized Psychopharmacology Seminars for Department of Medicine, Wadsworth Hospital, Los Angeles, CA
1979-1981Supervised clinical work in inpatient psychiatry of UCLA medical students and psychiatry residents, Neuropsychiatric Institute, UCLA, Los Angeles, CA
1982-PresentSupervised and lectured psychiatry residents, psychology interns, and medical students, in the outpatient department of the Neuropsychiatric Institute, UCLA, Los Angeles, CA
1983-PresentNumerous public speaking engagements at hospitals, universities and clinics on various topics in psychopharmacology and the pathophysiology of schizophrenia. 
1983-2012International speaker for Pfizer and Bristol-Myers-Squibb; National speaker for Ciba-Geigy, Pfizer, Searle, Lilly, Glaxo-Burroughs-Wellcome, Bristol-Myers Squibb, Wyeth and Abbott Laboratories; regional speaker for Pfizer, Dista, Sandoz Pharmaceuticals, Searle, UpJohn, Bristol-Myers-Squibb, and Mead Johnson; local speaker for Organon, Astra-Zeneca, and Parke-Davis
1984-1995Coordinate and help run anxiety and mood disorders seminars for UCLA psychiatry residents and psychology interns. 
1985Chaired an Anxiety Disorders Symposium sponsored by Wyeth Laboratories
1995-PresentPresent Advanced Psychopharmacology lectures to UCLA Psychiatry Residents
1996-PresentChair a journal club for UCLA psychiatry faculty

Principal Clinical and Hospital Service Responsibilities:

1981-1982Psychiatrist in Charge, Bowditch Hall Clinical Research Unit, McLean Hospital, Belmont, MA
1982-1987Assistant Director, UCLA Outpatient Psychiatry Department
1982-1983Assistant Director, UCLA Affective Disorders Clinic, Los Angeles,CA
1983-1987Director, Outpatient Psychopharmacology, Neuropsychiatric Institute,
UCLA, Los Angeles, CA
1984-1987Director, Anxiety Disorder Treatment Program, Neuropsychiatric Institute,
UCLA, Los Angeles, CA
1984-2011Medical Director for the UCLA Family Study of Schizophrenia
1988-1992Director, Intensive Care Unit, Westwood Hospital, Los Angeles, CA
1988-2003President, Pacific Psychopharmacology Research Institute, Santa Monica, CA

Media Experience:

1982-PresentNumerous radio and television interviews
1986Co-wrote and moderated two Art Ulene productions for ABC: “Panic Disorder” and “Obsessive-Compulsive Disorder”.
1986Wrote and moderated two C.M.E. network video productions: “The Pharmacokinetics of Benzodiazepines” and “Panic Disorder”
1987Interview on KTWV radio about the holiday blues and seasonal depression
1988Interview on KTWV radio about the holiday blues and seasonal depression
2000Web-casting, lectures from the UCLA Web studio on psychopharmacology
2012-2016Editor of Efocus, the continuing medical education electronic journal of the APA

Reviewer for: 

  • American Journal of Psychiatry (1982-present)
  • Journal of Clinical Psychopharmacology (1988-present)
  • British Medical Journal Open (2020-present)
  • Brain and Behavior (2014-present)
  • Journal of Neuropsychiatry and Clinical Neurosciences (1996-present)
  • American Psychiatric Association “Practical Guidelines” Series (Fall 1991)
  • Consultant for American Psychiatric Association Practice Guidelines for Eating Disorders, American Journal of Psychiatry, Vol. 150, No. 2, Feb. 1993, p. 207-288
  • Consultant for American Psychiatric Association Practice Guidelines for the Treatment of Patients With Bipolar Disorder, American Journal of Psychiatry 151:12, Dec. 1994 Supplement
  • Schizophrenia Research (2007-present)
  • Consultant for American Psychiatric Association Practice Guidelines for the Treatment of Patients With Bipolar Disorder, American Journal of Psychiatry; 2009 Edition.
  • eFOCUS, the continuing electronic medical education journal for the American Psychiatric Association

Biography:

            Journals:

  • Fogelson, D.L.; Marder, S.R.; Van Putten, T.:  “Dialysis for Schizophrenia:  Review of Clinical Trials and Implications for Further Research”, Am J Psychiatry, 137:605-607, 1980.
  • Fogelson, D.L.; Cohen, B.M.; Pope, Jr., H.G.:  “DSM III Schizophreniform Disorder”, Am J Psychiatry, 139:1281-1285, 1982.
  • Arana, G.W.; Berreira, P.J.; Cohen, B.M.; Lipinski, J.F.; Fogelson, D.L.:  “The Dexamethasone Suppression Test in Psychotic Disorders”, Am J Psychiatry, 140:1521-1523, 1983.
  • Nuechterlein, K.H.; Snyder, K.; Dawson, M.; Rappe, S.; Gitlin, M.; Fogelson, D.L.: “Expressed Emotion, Fixed Dose Fluphenazine Treatment, and Relapse in Recent-Onset Schizophrenia”, Psychopharmacology Bulletin, 22(3):633-639,1986.
  • Gitlin, M.J.; Midha, K.K.; Fogelson, D.L.; Nuechterlein, K.H.: “Persistence of Fluphenazine in Plasma After Decanoate Withdrawal”, J. Clin Psychopharmacol, 8(1):53-56, 1988.
  • Fogelson, D.L.; Bystritsky, A.; Sussman, N.: “Inter-Relationships Between Major Depression and the Anxiety Disorders: Clinical Relevance”, Psychiatric Annals, 18(3):158-167, 1988.
  • Nuechterlein, K.H.; Dawson, M.; Ventura, J.; Fogelson, D.L.; Gitlin, M.; Mintz, J.: “Testing Vulnerability Models: Stability of Potential Vulnerability Indicators Across Clinical State”, In H. Haefner and W.F. Gattaz (Eds.) Search for the Causes of Schizophrenia, Vol. 2. Springer-Verlag Berlin Heidelberg, 1990.
  • Clomipramine Study Group (Fogelson, D.L., member of group): “Clomipramine in the Treatment of Patients With Obsessive-Compulsive Disorder”, Arch Gen Psychiatry, 48(8):730-738, 1991.
  • Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Subotnik, K.; Talovic, S.A.: “Interrater Reliability of the Structured Clinical Interview for DSM-III-R, Axis II: Schizophrenia Spectrum and Affective Spectrum Disorders”, Psych Research, 39:55-63, 1991.
  • Fogelson, D.L.; Bystritsky, A.: “Imipramine in the Treatment of Obsessive Compulsive Disorder With and Without Major Depression”, Annals of Clin. Psychiatry, 3(3):233-237, 1991.
  • Fogelson, D.L.; Jacobson, S.; Sternbach, H.: “A Retrospective Study of Valproate in Private Practice”, Annals of Clin. Psychiatry, 3(4):315-320, 1991.
  • Fogelson, D.L., Epitome: Obsessive Compulsive Disorder, The Western Journal of Medicine, 155(5):522, 1991.
  • Goldstein, M.J.; Talovic, S.A.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik, K.L.; Asarnow, R.F.: “Family Interaction Versus Individual Psychopathology: Do They Indicate the Same Processes in the Families of Schizophrenics?”, British Journal of Psychiatry, Suppl., 161(18):97-102, 1992.
  • Bystritsky, A.; Fogelson, D.L.; Doctor, R.; Yager, J.: “Symptom Differences Among Anxiety Patients in Clinics with Differing Treatment Orientations: A Pilot Investigation”, J. Psychotherapy, 2(2), Spring 1993.
  • Fogelson, D.L.; Bystritsky, A.; Pasnau, R.: “Bupropion in the Treatment of Bipolar Disorders: The Same Old Story?”, J. Clinical Psychiatry, 53:443-446, 1992.
  • Subotnik, K.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein, M.J.; Talovic, S.A.: “Depressive Symptoms in the Early Course of Schizophrenia: Relationship to Familial Psychiatric Illness”, Am J Psych, 151(11):1551-1556, 1997.
  • Gitlin, M.; Nuechterlein, K.H.; Mintz, J.; Fogelson, D.L.; Bartzokis, G.; Aravagiri, M.: “Fluphenazine Levels During Maintenance Treatment of Recent Onset Schizophrenia: Relation to Side Effects, Psychosocial Function and Depression”, Psychopharmacology 148:350-354, 2000.
  • Fogelson, D.L., Nuechterlein, K.H.H., Asarnow, R.F.F., Payne, D.L., Subotnik, K.L, Giannini, C.: “The Factor Structure of Schizophrenia Spectrum Signs and Symptoms in First-Degree Relatives of Schizophrenic Patients from the UCLA Family Members Study”, Psychiatry Research 87:137-146, 1999.
  • Asarnow, R.F., Nuechterlein, K.H., Fogelson, D.L., Subotnik, K.L., Payne, D.L., Russell, AT., Asamen, J., Kuppinger, H., Kendler, K.S., Schizophrenia and Schizophrenia Spectrum Personality Disorders in the First-Degree Relatives of Children with Schizophrenia: The UCLA Family Members Study, Arch of General Psychiatry, 58:581-588, 2001.
  • Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M, Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry, 158(11):1835-42, 2001.
  • Asarnow R, Nuechterlein K, Asamen J, Fogelson DL, Subotnik KL, Zaucha K, Guthrie D: Neurocognitive functioning and schizophrenia spectrum disorders can be independent expressions of familial liability for schizophrenia in community control children: the UCLA family study, Schizophrenia Research. 54:111-120, 2002.
  • Neuchterlein KH, Asarnow RF, Subotnik KL, Fogelson DL, Payne DL, Kendler KS, Neale MC, Jacobson KC, Mintz J: The Structure of Schizotypy: Relationships Between Neurocognitive and Personality Disorder Features in Relatives of Schizophrenic Patients in the UCLA Family Study. Schizophrenia Research, 54:121-130, 2002. Asarnow RF, Nuechterlein KH, Subotnik KL, Fogelson DL, Torquato RD, Payne DL, Asamen J, Mintz J, Guthrie D: Neurocognitive Impairments in Non-psychotic Parents of Children with Schizophrenia and Attention Deficit Disorder: The UCLA Family Study. Arch of General Psychiatry, 59:1053-1060, 2002.
  • Fogelson DL, Nuechterlein KH, Asarnow RF, Payne DL, Subotnik KL. Validity of the family history method for diagnosing schizophrenia, schizophrenia-related psychoses, and schizophrenia-spectrum personality disorders in first-degree relatives of schizophrenia probands. Schizophr Res, 68:309-17, 2004.
  • Subotnik KL, Asarnow RF, Nuechterlein KH, Fogelson DL, Thorpe TI, Payne DL, Giannini CA, Kuppinger HE, Torquato RD, Mintz J, Hwang SS, Gottesman II. MMPI vulnerability indicators for schizophrenia and attention deficit disorder: UCLA family study of biological parents of offspring with childhood-onset schizophrenia or ADHD. Behav Genet., 35(2):159-75, 2005.
  • Fogelson DL, Nuechterlein KH, Asarnow RA, Payne DL, Subotnik KL, Jacobson KC, Neale MC, Kendler KS: Avoidant personality disorder is a separable schizophrenia-spectrum personality disorder even when controlling for the presence of paranoid and schizotypal personality disorders The UCLA family study. Schizophr Res, 91:192-9, 2007. Fogelson DL, Asarnow RA, Sugar CA, Subotnik KL, Jacobson KC, Neale MC, Kendler KS, Kuppinger H, Nuechterlein KH. Avoidant personality disorder symptoms in first-degree relatives of schizophrenia patients predict performance on neurocognitive measures: The UCLA family study. Schizophr Res, 2010 Jan 4, Ahead of Print.
  • Fogelson, D., & Kagan, B. (2020). Bipolar spectrum disorder masquerading as treatment resistant unipolar depression. CNS Spectrums, 1-3.
  • Fernandez V, Asarnow R, Narr K, Subotnik, KL, Kuppinger H, Fogelson DL, Nuechterlein KH. Temporal Lobe Thickness and Verbal Memory in First-degree Relatives of Individuals with Schizophrenia. Schizophr Res, Ahead of Print
  • Fogelson DL, and Kagan BL (2022). Bipolar spectrum disorder masquerading as treatment resistant unipolar depression. CNS Spectrums 27(1), 4–6. 2021
  • Sones, CS, Fogelson DL, Glick ID, Shader RI. Untreated Mental Illness has Created a National Tragedy: A Pandemic of Homelessness. Journal of Clinical Psychopharmacology, 42:115-117

Biography

            Letters:

  • Fogelson, D.L.: “Using Carbamazepine Effectively”, Am J Psychiatry, 141:1130, 1984.
  • Fogelson, D.L.: “Lorazepam and Oxazepam in the Treatment of Panic Disorder”. J. Clin Psychopharmacology, 8(2):150-151,1988.
  • Fogelson, D.L.: “Weight Gain During Fluoxetine Treatment”, J. Clin Psychopharmacology, 11(3):220, 1991.
  • Fogelson, D.L.: “Nefazodone and/or Sodium Tetradecyl Sulfate Associated Leukopenia, Fever and Shaking Chills in a Patient with Premenstrual Dysphoric Disorder”, J. Clin Psychopharmacology, 17(3):222-223, 1997.
  • Fogelson, D.L.; Sternbach, H.: “Lamotrigine Treatment of Refractory Bipolar Disorder”, J. Clin Psychiatry, 58(6):271-273, 1997.
  • Fogelson, D.L.: “Fenfluramine and the Cytochrome”, P450 System. Am. J. Psychiatry, 154(3):436-437, 1997.
  • Fogelson, D.L.; Sternbach, H.; Payne, D.: “A Naturalistic Pilot Study Comparing Haloperidol, Clozapine, Sertindole, and Risperidone in Partially Responsive Chronic Schizophrenia or Schizoaffective disorder”, J Clin Psychopharmacology, 17(6):492-494, 1997.
  • Fogelson DL, Leuchter A.: “Defining Treatment Resistant Depression” JAMA Psychiatry. 2017 Jul 1;74(7):758-759.

Biography

            Abstracts:

  • Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein, M.J.; Mintz, J.: “Depressive Symptoms in Recent-Onset Schizophrenia Patients Are Associated With a Family History of Depression”. Presented at theAmerican Psychiatric Association annual meeting. May 21, 1997, San Diego, CA.
  • Nuechterlein, K.H.; Subotnik, K.L.; Asarnow, R.F.; Gottesman, I.; Fogelson, D.L.; Payne, D.L.; Torquato, R.D.: “MMPI Profiles of First-Degree Relatives of Recent-Onset Schizophrenia Probands”. Presented at the International Congress on Schizophrenia Research 1997.
  • Asarnow, R.F.; Nuechterlein, K.H.; Torquato, R.D.; Subotnik, K.L.; Fogelson,D.L.: “Cognitive/Neuropsychological Abnormalities in the Parents of Children with a Schizophrenic Disorder”. Presented at the International Congress on Schizophrenia Research 1997.
  • Gottesman, I.I.: “MMPI Differences Among First-Degree Relatives of Probands with Childhood-Onset Schizophrenia, Attention Deficit Disorder, and Normal Control Children”. Presented at the International Congress on Schizophrenia Research 1997.
  • Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.L.; Subotnik, K.L.; Giannini, C.: “The Factor Structure of Schizophrenia Spectrum signs and Family
  • Members Study”. Presented at the International Congress on Schizophrenia Research 1997.
  • Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Goldstein, M.J., Fogelson, D.L.; Richard D. Torquato: “Communication Deviance is Associated with Putative Genetic Vulnerability Indicators in Relatives of Schizophrenia Patients”. Presented at the International Congress on Schizophrenia Research, 1999.
  • Fogelson, D.L.; Torquato, R.D.; Asarnow, R.F.; Subotnik, K.L.: “Are Categorical or Dimensional Approaches to Personality Disorders Better for Discriminating the Biological Parents of Probands with Childhood-Onset Schizophrenia Versus ADD”. Presented at the International Congress on Schizophrenia Research, 1999.
  • Nuechterlein, K.H.; Subotnik, K.L.; Gitlin, M.; Dawson, M.E.; Ventura, J.; Snyder, K.S.; Fogelson, D.L.; Shaw, S.; Mintz, J.: “Neurocognitive and Environmental Contributors to Work Recovery After Initial Onset of Schizophrenia: Answers from Path Analyses”. Presented at the International Congress on Schizophrenia Research, 1999.
  • Payne, D.L.; Kuppinger, H.E.; Asarnow, R.F.; Subotnik, K.L.; Fogelson, D.L.; Nuechterlein, K.H.: “Examination of Wisconsin Psychosis-Proneness Scales as an Indication of Familial Vulnerability to Schizophrenia”. Presented at the International Congress on Schizophrenia Research, 1999.
  • Asarnow, R.F.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik, K.L.; Torquato, R.D.; Payne, D.L.; Kuppinger, H.E.: “Defining the Boundaries of the Schizophrenia Phenotype: The UCLA Family Study”. Presented at the International Congress on Schizophrenia Research, 1999.
  • Subotnik, K.L.; Asarnow, R.F.; Fogelson, D.L.; Gottesman, I.I.; Thorpe, T.; Payne, D.L.; Giannini, C.; Torquato, R.; Kuppinger, H.E.; Nuechterlein, K.H.: “MMPI Vulnerability Indicators for Schizophrenia: Findings from the UCLA Family Study Examining Biological Parents of Children with Schizophrenia or Attention Deficit Disorder and Parents of Community Controls”. Presented at the 2nd International Conference on Early Psychosis March 31, 2000. New York.
  • Asarnow, R.F.; Nuechterlein, K.H.; Subotnik, K.L.; Fogelson, D.L.; Torquato, R.D.; Payne, D.L.; Guthrie, D.: “Specificity of Neurocognitive Impairments in Parents of Probands with Childhood Onset of Schizophrenia”. Presented at the International Congress on Schizophrenia Research, 2001.
  • Subotnik, K.L.; Nuechterlein, K.H.; Gitlin, M.; Siegel, B.; Bartzokis, G.; Fogelson, D.L.; Ventura, J.: “First Episode Patients Treated With Risperidone Show Better Neurocognitive and Functional Outcome Than Patients Treated with Fluphenazine Decanoate”. Presented at the International Congress on Schizophrenia Research, 2001.
  • Nuechterlein, K.H.; Asarnow, R.F.; Jacobson, K.; Subotnik, K.L.; Neale, M.; Fogelson, D.L.; Kendler, K.: “Neurocognitive Vulnerability Factors in First-Degree Relatives of Schizophrenic Probands Show Accelerated Aging Effects”. Presented at the International Congress on Schizophrenia Research, 2001.
  • Yee, C.M.; Nuechterlein, K.H.; Morris, S.E.; Gitlin, M.J.; Fogelson, D.L.; Bartzokis, G.; Subotnik, K.L.: “Rates of Smoking in Recent-onset Schizophrenia Patients Receiving Traditional Versus Atypical Antipsychotic Medications”. Presented at the International Congress on Schizophrenia Research, 2001.
  • Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.; Subotnik, K.L.; Kuppinger, H.: “Validity of the Family History Method for Diagnosing Schizophrenia and Schizophrenia related Psychoses in First-Degree Relatives of Schizophrenic Probands”. Presented at the International Congress on Schizophrenia Research, 2001.
  • Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.; Jacobson, K.C.; Neale, M.C.; Kendler, K.S.: “Avoidant Personality Disorder Increases the Detection of First Degree Relatives Affected by a Schizophrenia Spectrum Diagnosis”. Accepted to the International Congress on Schizophrenia Research, 2003.
  • Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Payne, D.L.; Ventura, J.; Kendler, K.S.:”Relationship between positive and negative symptoms of schizophrenia and dimensions of personality pathology in biological parents”. Accepted to the International Congress on Schizophrenia Research, 2003.
  • Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.; Jacobson, K.C.; Neale, M.C.; Kendler, K.S.; Sugar, C.: “Avoidant Personality Disorder Symptoms in First-Degree Relatives of Schizophrenics Predict Performance on Neurocognitive Measures The UCLA Family Study”. Presented at the International Congress on Schizoprhenia Research, 2009
  • Kenneth L. Subotnik, Robert F. Asarnow, David L. Fogelson, Kenneth S. Kendler, Heidi E. Kuppinger, Stephanie M. Woo, Brooke L. Bayles, Keith H. Nuechterlein:Schizophrenia and Schizophrenia-Spectrum Disorders in the First-Degree Relatives of Children and Adults with Schizophrenia: The UCLA Family Study. Presented at the International Congress on Schizophrenia Research, 2017

Biography:

            Invited Articles:

Joan Rosenbaum Asarnow, PhDDavid Fogelson, MDOlivia FitzpatrickJennifer Hughes, MD: Child and Adolescent Suicide and Self Harm: Treatment and Prevention; Dec 26, 2018; Volume: 35Issue: 12

            Chapters

  • Co-author of the Psychiatric Knowledge and Skills Assessment Program – Anxiety Disorders Section, American Psychiatric Association
  • Lenzenweger, M.F. & Dworkin, R.H. (Eds.). (in press). The Pathogenesis of Schizophrenia: An Experimental Psychopathology Perspective. Washington, DC:American Psychological Association. Chapter on: Neurocognitive VulnerabilityFactors for Schizophrenia: Convergence Across Genetic Risk Studies and Longitudinal Trait/State Studies. Nuechterlein, K.H., Asarnow, R.F., Subotnik, K.L., Fogelson, D.L., Ventura, J., Torquato, R.D., Dawson, M.E.

Biography:

            Research:

  • Clinical research trials run at the Pacific Psychopharmacology Research Institute:
  • Anafranil multicenter trial, 1986-1987, Ciba Geigy, for Obsessive Compulsive Disorder, placebo controlled.
  • Buspar multicenter trial, 1987-1988, Mead Johnson, for Xanax withdrawal, phase IV.
  • Tandospirone multicenter trial, 1989-1990, Pfizer, for Panic Disorder, placebo controlled.
  • Tandospirone multicenter trial, 1991-1992, Pfizer for Major Depression, placebo controlled.
  • Ondansetron multicenter trial, 1991, Glaxo, for Generalized Anxiety Disorder, placebo controlled.
  • Anafranil multicenter trial, 1991-1993, Ciba Geigy, for Obsessive Compulsive Disorder with Depression.
  • Brofaromine multicenter trial, 1992-1993, Ciba Geigy, for Social Phobia, placebo controlled.
  • Fluvoxamine multicenter trial, 1992, Upjohn, for Panic Disorder, placebo controlled.
  • Sertindole multicenter trial, 1994, Abbott labs, for Schizophrenia.
  • Lamictal multicenter trial, 1997, Glaxo-Wellcome labs, for Bipolar Depression
  • Aripiprazole multicenter trial, 1998, Otsuka, for Schizophrenia
  • Ziprasidone multicenter trial, 1998-2003, Otsuka, for Schizophrenia
  • Substance P Antagonist multicenter trial, 1999, Novartis, for Social Phobia. 11 patients were randomized.
  • Fluoxetine-Olanzapine multicenter trial, 2000, Eli Lilly for Treatment resistant Depression
  • 193 98 203 multicenter trial, 2000, Otsuka for Major Depression
  • Leviteracetam, multicenter trial, 2003, USB Pharma, Social Phobia

Forensic Case Log:

1.  G. Greg Aftergood

gga@aftergoodlaw.com

Dr. Fogelson was the doctor for our opposition in the matter of the Eva J. Toureau Revocable Trust, Case No. LP 012 190

2.  Steven D. Fondiler

sfondiler@aol.com

case was related to Northridge Hospital; attorney does not have case name or number

3.  Howard Krom

howard@haklaw.com

For your records, the case you worked on with Robert Cohen and myself in 2014 was Ivy Chen Wang and Boss Litho Inc. v. New York Life Insurance Company (Case Number BC555271)

Howard A. Krom, Esq.

310 278-9988 (direct dial) 

310 614-4100 (cell)

howard@haklaw.com

4.  David L. Rosner

DLRosnerLaw@sbcglobal.net

  Medical Board of Calif v. Peter Swerdlick,M.D.  Case No.   06-2007-182598

5. Berna Warner Fredman

bernawarner@aol.com

Marriage of HAMALAINEN and CULLINANE, Case No. BD 550109

6. Joshua A. Burt

burtlegal.com

BurtLegal@BurtLegal.com

Leslie Roark v. Nissran Mahmoud.  The case number 56-2012-00410671-CU-PN-VTA

7. Lawrence Hait

lawhait@earthlink.net

Stephanie:
That matter was over 15 years ago, and I don’t recall the name or case number and the records have been destroyed.  I only worked the one case with Dr. Fogelson, who I thought was excellent.  Sorry.

8.  M. Lawrence Lallande Sr.

MLL@LallandeLaw.com

Jeffrey A. Milman

jmilman@hodesmilman.com

Jeffrey A. Milman, Esq. (SBN: 99072)

HODES MILMAN

9210 Irvine Center Drive

Irvine, California 92618

Phone: 949-640-8222

Fax:  949-336-8114

M. Lawrence Lallande, Sr. (SBN: 113663)

LALLANDE LAW, PLC

111 W. Ocean Blvd., 19th Floor

Long Beach, Ca  90802

Phone: 562-436-8800

Fax:  562-436-8810

Attorneys for Plaintiffs, MARK J. LEINGANG and ROBYN LEINGANG

SUPERIOR COURT OF CALIFORNIA

                                FOR THE COUNTY OF ORANGE

MARK J. LEINGANG, ROBYN LEINGANG,                                                                                                Plaintiffs,                   vs.   MON-TA TSAI, M.D., an individual; ERIC SPEARE, M.D., an individual; DANIEL J. HEADRICK, M.D., an individual; MARY ASHKENAZE, M.D., an individual; MICHAEL G. BOWER, M.D., an individual; SOUTH COAST MEDICAL CENTER, a California corporation; PACIFIC COAST RECOVERY CENTER, a business entity of unknown status, ST. JOSEPH HEALTH SYSTEM, a California Corporation and DOES 1 through 100, inclusive,                                                   Defendants.                                                     ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) CASE NO.:  CIVDS 909139   Assigned for All Purposes to: Honorable Thierry Patrick Colaw Department C-25       Action filed:  January 13, 2010   Trial date:  December 9, 2011

9. Tim O’Brien; Vanda Case

Timothy J. O’Brien

Patent Case involving Vanda Pharmaceuticals

Brand manufacturer is opposing generic production as patent infringement

I worked for the generic manufacturer

LATHAM & WATKINS LLP
330 North Wabash Avenue, Suite 2800
Chicago, IL 60611
Direct Dial: +1.312.876.6547
Fax: +1.312.993.9767
Email: timothy.obrien@lw.com
http://www.lw.com

10.        Norris v. Bijanpour et al. is an appropriate citation to the case. The case number is CV 15-5263. It is a federal claim located in the United States District Court in the Central District of California. The judge is Dolly Gee.

11.       :  United States ex rel. Valdez v. Aveta, Inc. et al., United States District Court for the District of Puerto Rico, Civil Action No. 3:15-cv-1140

Retained as expert witness in qui tam suit alleging violations of the False Claims Act.

12.  Lange v. Epiphany Care Homes.  Our clients: Jerry R. Bruns, M.D., and La Mer Psychiatric Medical Group, Inc. 

Case No. 56-2019-00528503-CU-PO-VTA.  LASC Dept. 41.